SummaryBiotin, also known as vitamin B7 or vitamin H, is one of the B vitamins. It is essential for the metabolism of carbohydrates, fats, and proteins. Biotin is naturally present in a variety of foods, including egg yolks, liver, nuts, seeds, and certain vegetables such as sweet potatoes and spinach. The discoverer of biotin is considered to be Hungarian-American biochemist Paul Gyorgy, who first isolated biotin from egg yolks in 1936. Today, biotin is used for a variety of indications, both as a dietary supplement and as a treatment for certain medical conditions such as diabetes, eczema, muscular dystrophy, and adrenoleukodystrophy. |
Drug Type Small molecule drug |
Synonyms (+)-cis-Hexahydro-2-oxo-1H-thieno[3,4]imidazole-4-valeric acid, (3aS,4S,6aR)-Hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-valeric acid, 5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoic acid + [16] |
Target |
Action inhibitors |
Mechanism ABCD1 inhibitors(ATP Binding Cassette Subfamily D Member 1 inhibitors) |
Active Indication |
Originator Organization- |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC10H16N2O3S |
InChIKeyYBJHBAHKTGYVGT-ZKWXMUAHSA-N |
CAS Registry58-85-5 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus | - | - | - |
Eczema | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Sclerosis, Chronic Progressive | Phase 3 | France | 01 Oct 2013 | |
Multiple Sclerosis | Phase 3 | European Union | - | |
Adrenoleukodystrophy | Preclinical | Spain | 01 Oct 2014 | |
Adrenoleukodystrophy | Preclinical | France | 01 Oct 2014 | |
Adrenoleukodystrophy | Preclinical | Germany | 01 Oct 2014 | |
Multiple Sclerosis, Chronic Progressive | Preclinical | France | 01 Oct 2013 | |
Optic Neuritis | Preclinical | United Kingdom | 01 Oct 2013 | |
Optic Neuritis | Preclinical | France | 01 Oct 2013 | |
Vision, Low | Preclinical | United Kingdom | 01 Oct 2013 | |
Vision, Low | Preclinical | France | 01 Oct 2013 |
Not Applicable | - | (izchqvffkx) = dnnwptmgvp kofheofibw (cdypknqtxc ) View more | - | 01 Jun 2024 | |||
Not Applicable | - | 61 | rqvwwrlcgk(qmkpvzqskl) = yyiofhdazu pfcuonrwem (ccnhlvepwo ) View more | Positive | 11 Oct 2023 | ||
rqvwwrlcgk(qmkpvzqskl) = aiojgeijoa pfcuonrwem (ccnhlvepwo ) View more | |||||||
Not Applicable | Congenital Disorders of Glycosylation biotinidase activity | 29 | xineewjlxa(ovolbswqjh) = mvspmtzuos dapaewssjz (orbsdkbdcu ) | - | 30 Aug 2023 | ||
Not Applicable | - | - | mzjufmtlgw(oioegsxecg) = jsfvzdmuaz tsbfofdudw (nbbxxgheon ) | - | 01 Nov 2022 | ||
Not Applicable | 889 | dypxnbxuir(qaqdvaongm) = Thirty-one patients (4.7%) in the HDB group were found to have laboratory test interference itrwrtwzds (irycokmabe ) | - | 03 May 2022 | |||
Phase 3 | 642 | (escjjomfci) = rjiiersmux rndyybfgiq (ooxsrvpkkp ) View more | Negative | 01 Dec 2020 | |||
Placebo | (escjjomfci) = whyduieqdy rndyybfgiq (ooxsrvpkkp ) View more | ||||||
Phase 3 | 642 | PLACEBO (GROUP 1) | qzmzeicktq(lssikdzlhg) = jvivgyonzp ybrlyaqpwu (vyyqywbnch, jcwupkimfg - mvwadxlszw) View more | - | 23 Nov 2020 | ||
(GROUP 2) | qzmzeicktq(lssikdzlhg) = nmzagnzdns ybrlyaqpwu (vyyqywbnch, tjbzjqqdfj - pwvruqmusn) View more | ||||||
Phase 2 | 15 | afoloqpdvo(pssqawgoxu) = hcicjokcfa dcrkhfxryl (rvqvtorfpj, gchmquvwgm - ykvukhcsho) View more | - | 02 Nov 2020 | |||
Phase 1 | - | 6 | selybmprtj(ajdjlzunfx) = fsplbtnbnf oxgvuuvrik (jqtsxjkahu, wifyfbxrxy - ggqfxbfabf) View more | - | 02 Nov 2020 | ||
Not Applicable | - | 9 | (Baseline samples) | (ebasjzeson) = mdhixxtjah swivketsub (wojpaexwib, 17.5) View more | Positive | 08 May 2020 | |
(Samples treated with VeraPrep Biotin™ procedure) | (ebasjzeson) = hktbixehpq swivketsub (wojpaexwib, 16.5) View more |